Christopher Cline Sells 1,014 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Christopher Cline sold 1,014 shares of Travere Therapeutics stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $42.61, for a total transaction of $43,206.54. Following the completion of the transaction, the chief financial officer owned 116,899 shares of the company’s stock, valued at $4,981,066.39. This represents a 0.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Stock Down 3.4%

Travere Therapeutics stock opened at $39.54 on Friday. Travere Therapeutics, Inc. has a 1-year low of $13.88 and a 1-year high of $43.31. The firm has a market capitalization of $3.65 billion, a price-to-earnings ratio of -131.80 and a beta of 0.86. The company has a current ratio of 2.74, a quick ratio of 2.70 and a debt-to-equity ratio of 2.71. The firm has a 50 day simple moving average of $29.77 and a 200 day simple moving average of $31.42.

Institutional Trading of Travere Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC lifted its holdings in shares of Travere Therapeutics by 60.4% during the 1st quarter. SG Americas Securities LLC now owns 54,691 shares of the company’s stock worth $1,625,000 after acquiring an additional 20,591 shares during the last quarter. Diversified Trust Co lifted its holdings in shares of Travere Therapeutics by 12.4% during the 1st quarter. Diversified Trust Co now owns 28,161 shares of the company’s stock worth $837,000 after acquiring an additional 3,117 shares during the last quarter. Rockefeller Capital Management L.P. lifted its holdings in shares of Travere Therapeutics by 1,604.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 2,642 shares of the company’s stock worth $101,000 after acquiring an additional 2,487 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Travere Therapeutics during the 4th quarter worth $278,000. Finally, Empowered Funds LLC bought a new stake in shares of Travere Therapeutics during the 4th quarter worth $115,000.

Travere Therapeutics News Summary

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in FSGS, materially expanding Travere’s rare‑kidney franchise and adding an estimated ~30,000 U.S. patients to the addressable market — the core reason for the earlier, large share price gain. Filspari approval article
• Positive Sentiment: Market reaction and analyst upgrades lifted sentiment and targets (examples: Canaccord, Guggenheim, Piper Sandler, HC Wainwright), reinforcing a re‑rating narrative and supporting higher medium‑term revenue expectations for Filspari. Guggenheim note
• Neutral Sentiment: Trading activity is elevated and options volumes spiked around the approval — this amplifies short‑term moves (both up and down) and suggests greater volatility while the market digests label details and early commercialization assumptions. Options activity report
• Neutral Sentiment: Company commentary and coverage (conference/transcript writeups, health press) are clarifying the label and launch plans, but concrete revenue/volume reads are not yet available — useful for modeling but not definitive. Company discussion
• Negative Sentiment: Multiple insiders (CEO, directors, CFO, other executives) sold material blocks of shares over the last two trading days — most sales were executed under pre‑arranged Rule 10b5‑1 plans or to cover taxes related to vesting, but the scale of selling can fuel near‑term downward pressure and signal profit‑taking after the approval‑driven rally. Example SEC filing for CEO sale. CEO Form 4
• Negative Sentiment: Some analysts warn that estimate‑revision trends and elevated expectations could limit near‑term upside — the stock may consolidate or pull back as investors re‑rate forward revenue assumptions. Zacks caution

Analyst Ratings Changes

TVTX has been the subject of a number of recent analyst reports. Piper Sandler upgraded shares of Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 price target for the company in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $47.00 price target on shares of Travere Therapeutics in a research report on Tuesday. Canaccord Genuity Group boosted their price target on shares of Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st. Finally, Guggenheim boosted their price target on shares of Travere Therapeutics from $49.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.50.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.